ATE412895T1 - Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression - Google Patents

Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression

Info

Publication number
ATE412895T1
ATE412895T1 AT06013455T AT06013455T ATE412895T1 AT E412895 T1 ATE412895 T1 AT E412895T1 AT 06013455 T AT06013455 T AT 06013455T AT 06013455 T AT06013455 T AT 06013455T AT E412895 T1 ATE412895 T1 AT E412895T1
Authority
AT
Austria
Prior art keywords
integrin expression
studying
inhibition
effect
angiogenesis inhibitor
Prior art date
Application number
AT06013455T
Other languages
English (en)
Inventor
Naoto Ono
Yasuhiro Funahashi
Taro Senba
Toshiaki Wakabayashi
Naoko Hata
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE412895T1 publication Critical patent/ATE412895T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06013455T 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression ATE412895T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21

Publications (1)

Publication Number Publication Date
ATE412895T1 true ATE412895T1 (de) 2008-11-15

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06013455T ATE412895T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
AT02700679T ATE350660T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02700679T ATE350660T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Country Status (12)

Country Link
US (1) US7122318B2 (de)
EP (2) EP1362601B8 (de)
JP (1) JP4255285B2 (de)
KR (1) KR20030080013A (de)
CN (2) CN100384482C (de)
AT (2) ATE412895T1 (de)
AU (1) AU2002233677B2 (de)
CA (1) CA2438427C (de)
DE (2) DE60217300T2 (de)
ES (2) ES2280502T3 (de)
HK (2) HK1059038A1 (de)
WO (1) WO2002066073A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412895T1 (de) 2001-02-21 2008-11-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
TW589181B (en) * 2001-09-05 2004-06-01 Eisai Co Ltd Lymphocytic activation inhibitor and remedial agent for autoimmune disease
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
AU2006261993B2 (en) 2005-06-22 2011-11-17 Plexxikon, Inc. Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0673937T3 (da) * 1993-09-10 2004-03-22 Eisai Co Ltd Bicyclisk heterocyclisk sulfonamid og sulfonsyreesterderivater
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
PT889876E (pt) * 1996-03-29 2001-11-30 Searle & Co Derivados de fenilenossulfonamidas meta-substituidas
AU733303C (en) * 1996-05-31 2002-08-08 Scripps Research Institute, The Methods and compositions useful for inhibition of angiogenesis
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
HUP0300544A3 (en) 2000-02-03 2005-03-29 Eisai Co Ltd Pharmaceutical compositions containing integrin expression inhibitors
ATE412895T1 (de) 2001-02-21 2008-11-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression

Also Published As

Publication number Publication date
DE60217300D1 (de) 2007-02-15
ATE350660T1 (de) 2007-01-15
EP1362601A1 (de) 2003-11-19
CN101025419A (zh) 2007-08-29
AU2002233677B2 (en) 2005-01-06
CN100384482C (zh) 2008-04-30
US20040132783A1 (en) 2004-07-08
HK1099363A1 (en) 2007-08-10
EP1362601B8 (de) 2007-02-28
EP1742052B1 (de) 2008-10-29
JP4255285B2 (ja) 2009-04-15
HK1059038A1 (en) 2004-06-18
EP1362601B1 (de) 2007-01-03
ES2280502T3 (es) 2007-09-16
DE60217300T2 (de) 2007-10-04
EP1362601A4 (de) 2005-07-06
CA2438427A1 (en) 2002-08-29
KR20030080013A (ko) 2003-10-10
CA2438427C (en) 2011-04-12
ES2317368T3 (es) 2009-04-16
CN1620313A (zh) 2005-05-25
EP1742052A1 (de) 2007-01-10
JPWO2002066073A1 (ja) 2004-06-17
DE60229676D1 (de) 2008-12-11
WO2002066073A1 (fr) 2002-08-29
US7122318B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
DE60229676D1 (de) Verfahren zur Untersuchung der Wirkung eines Angiogenese-Hemmers unter Vermittlung durch Hemmung der Integrin-Expression
DE60124736D1 (de) Vorrichtung zur messung des abschnittsweisen volumens und der elektrischen parallelleitfähigkeit einer herzkammer oder eines blutgefässes
DE50310307D1 (de) Verfahren und Vorrichtung zur schnellen tomographischen Messung der elektrischen Leitfähigkeitsverteilung in einer Probe
ATE511549T1 (de) Kit zur messung der thrombinerzeugung in einer blut- oder plasmaprobe eines patienten
WO2004113912A8 (en) System and method for determining a temperature during analysis of biological fluid
NO20071802L (no) Mikrostrukturinspesjonsapparat og mikrostrukturinspeksjonsfremgangsmate
BR0116158A (pt) Método e equipamento para uma medição de qualidade da forma de onda
AR041513A1 (es) Sensado de presion en consola quirurgica
DE60315151D1 (de) Diagnostischer test zur bestimmung der konzentration einer transienten proteolytischen aktivität in zusammengesetzten biologischen medien
ATE446561T1 (de) Sensoranordnung
CN101512011A (zh) 在生物介质中测定酶活性的方法
DE60316623D1 (de) Verfahren zur Messung der Endothelfunktion einer Person
Lawson et al. Tear strength of five elastomeric impression materials at two setting times and two tearing rates
ATE313788T1 (de) Feuchtigkeitsfühler mit kapazitivem feuchte- messelement und verfahren zur erfassung der luftfeuchtigkeit
DE60307448D1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
ATE530906T1 (de) Verfahren zur unterscheidung zwischen einen gemeinsamen analyten enthaltenden blut- und kontrollösungen
DE60112949D1 (de) Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes
ATE448496T1 (de) Verfahren und einrichtung zur hydrometeor- detektion
DE60203524D1 (de) Verfahren zur messung des arteriolendrucks
ATE472427T1 (de) Verfahren zur messung eines drucks
DE602008006604D1 (de) Verfahren zur verarbeitung von spaltkammermesssignalen
DE60313181D1 (de) Verfahren und vorrichtung zur bestimmung eines phasenübergangs einer substanz
ATE287663T1 (de) Verfahren zur bestimmung der belastbarkeit eines menschen
ATE535776T1 (de) Verfahren zur erkennung von dentalen oberflächenstrukturen
ATE397664T1 (de) Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1742052

Country of ref document: EP